Cassava Sciences, Inc. Warrant

Cassava Sciences, Inc. is a biotechnology firm currently in the clinical development stage, dedicated to discovering therapies for neurodegenerative disorders. Their key therapeutic asset is simufilam, a small molecule drug that has already completed its Phase 2b clinical evaluation. Furthermore, the company is advancing SavaDx, a diagnostic tool utilizing blood-based biomarkers for the early detection of Alzheimer's disease. Incorporated in 1998, the organization was previously known as Pain Therapeutics, Inc. until its name change to Cassava Sciences, Inc. in March 2019. The company's headquarters are located in Austin, Texas.